These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35052849)

  • 21. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration.
    Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL
    Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
    Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
    Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment.
    Takahashi M; Saito K; Ai T; Nojiri S; Khasawneh A; Paran FJ; Horiuchi Y; Takei S; Yamamoto T; Wakita M; Hiki M; Miida T; Naito T; Takahashi K; Tabe Y
    PLoS One; 2023; 18(1):e0279779. PubMed ID: 36693058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.
    Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC
    Front Immunol; 2022; 13():920333. PubMed ID: 35865529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination.
    Takahashi T; Ai T; Saito K; Nojiri S; Takahashi M; Igawa G; Yamamoto T; Khasawneh A; Paran FJ; Takei S; Horiuchi Y; Kanno T; Tobiume M; Hiki M; Wakita M; Miida T; Okuzawa A; Suzuki T; Takahashi K; Naito T; Tabe Y
    PLoS One; 2023; 18(9):e0291670. PubMed ID: 37725623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination.
    Tobudic S; Simader E; Deimel T; Straub J; Kartnig F; Heinz LX; Mandl P; Haslacher H; Perkmann T; Schneider L; Nothnagl T; Radner H; Winkler F; Burgmann H; Stiasny K; Novacek G; Reinisch W; Aletaha D; Winkler S; Blüml S
    Front Med (Lausanne); 2023; 10():1049157. PubMed ID: 36844197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
    Bordalo Ferreira F; Rafael MA; Coimbra L; Boavida N; Arrobas F; Pereira Correia F; Martins Figueiredo L; Carvalho E Branco J; Carvalho Lourenço L; Santos L; Oliveira AM
    Vaccine; 2023 Jun; 41(26):3862-3871. PubMed ID: 37202269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON].
    Doherty J; Morain NO; Stack R; Girod P; Tosetto M; Inzitiari R; Sheridan J; Cullen G; McDermott E; Buckley M; Horgan G; Mulcahy H; Ryan EJ; Daghfal D; Doran P; Morain CO; Doherty GA
    J Crohns Colitis; 2022 Sep; 16(9):1354-1362. PubMed ID: 35176770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers.
    Infantino M; Manfredi M; Stacchini L; Cosma C; Grossi V; Lari B; Russo E; Amedei A; Benucci M; Veneziani F; Casprini P; Catalano CM; Cirrincione G; Bonaccorsi G; Pompetti A
    Clin Chem Lab Med; 2022 May; 60(6):934-940. PubMed ID: 35303766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
    Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reactogenicity and immunogenicity of the intradermal administration of BNT162b2 mRNA vaccine in healthy adults who were primed with an inactivated SARS-CoV-2 vaccine.
    Temtanakitpaisan Y; Saengnipanthkul S; Sarakosol N; Maskasame S; Mongkon S; Buranrat B; Thammawat S; Patamatamkul S; Nernsai P
    Vaccine X; 2022 Dec; 12():100242. PubMed ID: 36415450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease.
    Stercel V; Lóczi L; Kadenczki O; Nemes É; Nagy B; Hodossy-Takács R; Szabó AÁ; Fagyas M; Kappelmayer J; Szabó T; Bagoly Z
    Front Immunol; 2023; 14():1257072. PubMed ID: 37965328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
    Shehab M; Alrashed F; Alfadhli A; Alsayegh A; Aldallal U; Alsayegh M; Cherian P; Alkhair I; Thanaraj TA; Channanath A; Dashti AA; Albanaw A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
    Front Med (Lausanne); 2022; 9():933996. PubMed ID: 35860742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
    Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study.
    Koehm M; Klippstein M; Dauth S; Hallmann K; Kohmer N; Burkhardt H; Ciesek S; Geisslinger G; Rabenau HF; Behrens F
    RMD Open; 2023 Aug; 9(3):. PubMed ID: 37652553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of COVID-19 Vaccination on the Levels of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Naive, Hybrid, and Breakthrough SARS-CoV-2 Recovered Indian Individuals.
    Deepika G; Adarsh S; Sadhana Y; Srihitha M; Veeraiah N; Reddy DN
    J Lab Physicians; 2023 Sep; 15(3):377-382. PubMed ID: 37564232
    [No Abstract]   [Full Text] [Related]  

  • 37. Estimation of SARS-CoV-2 Neutralizing Activity and Protective Immunity in Different Vaccine Types Using Three Surrogate Virus Neutralization Test Assays and Two Semiquantitative Binding Assays Targeting the Receptor-Binding Domain.
    Lee B; Ko JH; Lee KH; Kim YC; Song YG; Park YS; Baek YJ; Ahn JY; Choi JY; Song KH; Kim ES; Bae S; Kim SH; Jeong HW; Kim SW; Kwon KT; Kim SH; Jeong H; Kim B; Kim SS; Choi WS; Peck KR; Kang ES
    Microbiol Spectr; 2022 Dec; 10(6):e0266922. PubMed ID: 36250875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors.
    Venerito V; Stefanizzi P; Martinelli A; Fornaro M; Galeone MG; Tafuri S; Iannone F; Lopalco G
    Clin Exp Rheumatol; 2023 Jan; 41(1):166-169. PubMed ID: 36441661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
    Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.